For example, a project generating over 100 new jobs and stimulating local growth in an economically disadvantaged area might ...

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

The alliance brings together Cellular Origins, a company focusing on applying robotics and other forms of automation to CGT ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

The US healthcare system continues to burden patients with complexity, fragmentation, and out-of-pocket costs they weren't prepared to shoulder.

At BIO 2025 in Boston today, pharma and biotech leaders discussed the current state of AI in the drug development life cycle.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Discover the essential factors required to successfully scale GenAI in the pharmaceutical industry, from pilot programmes to impactful implementation. Gain insights on the challenges and ...